A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Active, not recruiting · Phase 2 · NCT01594723
Conditions: Neoplasms, Hematologic
At a glance
- Research payments reported, 2025
- $1,652
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 110
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- 120 mg LY2784544 (drug)
- Dates
- Started 2012-05-22; completion 2026-12
- Results posted
- Not yet
The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.
From ClinicalTrials.gov, last updated 2026-06-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1,652 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Methodist Childrens Hospital DBA Covenant Childrens Hospital $1,652
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.